AstraZeneca Wins EU Label Expansion for Trixeo in Asthma (AZN)
11 Articles
11 Articles
canaledieci.it
In our country, bronchial asthma affects almost 3 million Italians, about 5% of the Italian population. In Europe, asthma affects 43 million people and, every year, nearly 4 million people receive a new diagnosis. When not controlled with dual therapy, patients can experience symptoms such as wheezing, shortness of breath, sense [...]
The European Commission has approved budesonide/glycopyrronium/formoterol fumarate (BGF) as maintenance treatment for asthma in patients 12 years of age and older who are not adequately controlled with ICS/LABA. Lupinok is based on the results of Phase III studies KALOS and LOGOS The post AstraZeneca, triple BGF therapy approved in the EU as maintenance treatment for asthma appeared first on Quotidiano Sanità.
AstraZeneca’s Trixeo Aerosphere Approved in the European Union as First Triple-Combination Maintenance Therapy for Asthma in Patients Aged 12 and Older
(IN BRIEF) AstraZeneca’s Trixeo Aerosphere has been approved by the European Commission as a maintenance treatment for asthma in patients aged 12 years and older whose disease is not adequately controlled by medium-dose ICS/LABA therapy. AstraZeneca describes Trixeo as the … Read the full press release →
AstraZeneca AstraZeneca announced that the European Commission has approved Trixeo Aerosphere, the triple combination of budesonide/glycopyrronium/formoterol fumarate (BGF) (320/28.8/10 μg), as an asthma maintenance treatment in patients from 12 years of age whose disease is not adequately controlled by a combination of a medium-dose inhaled corticosteroid (CI) and a long-acting beta-2 agonist (LABA).The treatment combines an inhaled corticoster…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
